Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy LogicBio Therapeutics stock
Learn how to easily invest in LogicBio Therapeutics stock.
LogicBio Therapeutics Inc is a biotechnology business based in the US. LogicBio Therapeutics shares (LOGC) are listed on the NASDAQ and all prices are listed in US Dollars. LogicBio Therapeutics employs 62 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in LogicBio Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LOGC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
LogicBio Therapeutics stock price (NASDAQ: LOGC)Use our graph to track the performance of LOGC stocks over time.
LogicBio Therapeutics shares at a glance
|Latest market close||$0.40|
|52-week range||$0.34 - $5.15|
|50-day moving average||$0.48|
|200-day moving average||$1.94|
|Wall St. target price||$6.25|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.12|
Buy LogicBio Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy LogicBio Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
LogicBio Therapeutics price performance over time
|1 week (2022-06-24)||-7.79%|
|1 month (2022-06-03)||-22.25%|
|3 months (2022-04-01)||-44.93%|
|6 months (2022-01-03)||-84.08%|
|1 year (2021-07-02)||-90.82%|
|2 years (2020-07-02)||-95.23%|
|3 years (2019-07-03)||11.32|
|5 years (2017-06-29)||N/A|
LogicBio Therapeutics financials
|Revenue TTM||$7.8 million|
|Gross profit TTM||$-22,759,000|
|Return on assets TTM||-35.19%|
|Return on equity TTM||-92.02%|
|Market capitalisation||$14.2 million|
TTM: trailing 12 months
LogicBio Therapeutics share dividends
We're not expecting LogicBio Therapeutics to pay a dividend over the next 12 months.
LogicBio Therapeutics share price volatility
Over the last 12 months, LogicBio Therapeutics's shares have ranged in value from as little as $0.34 up to $5.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LogicBio Therapeutics's is 1.4863. This would suggest that LogicBio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
LogicBio Therapeutics overview
LogicBio Therapeutics, Inc. , a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Frequently asked questionsWhat percentage of LogicBio Therapeutics is owned by insiders or institutions?
Currently 8.934% of LogicBio Therapeutics shares are held by insiders and 49.487% by institutions. How many people work for LogicBio Therapeutics?
Latest data suggests 62 work at LogicBio Therapeutics. When does the fiscal year end for LogicBio Therapeutics?
LogicBio Therapeutics's fiscal year ends in December. Where is LogicBio Therapeutics based?
LogicBio Therapeutics's address is: 65 Hayden Avenue, Lexington, MA, United States, 02421 What is LogicBio Therapeutics's ISIN number?
LogicBio Therapeutics's international securities identification number is: US54142F1021 What is LogicBio Therapeutics's CUSIP number?
LogicBio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 54142F102
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert